These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 6990673)
1. Beta-cell function and metabolic control in insulin treated diabetics. Madsbad S; McNair P; Faber OK; Binder C; Christiansen C; Transbøl I Acta Endocrinol (Copenh); 1980 Feb; 93(2):196-200. PubMed ID: 6990673 [TBL] [Abstract][Full Text] [Related]
2. Residual beta cell function in insulin-dependent diabetes: evaluation by circadian determination of C-peptide immunoreactivity. Canivet B; Harter M; Viot G; Balarac N; Krebs BP J Endocrinol Invest; 1980; 3(2):107-11. PubMed ID: 6993546 [TBL] [Abstract][Full Text] [Related]
3. Residual pancreatic function in insulin dependent diabetics. Glatthaar C; Beaven DW; Donald RA; Smith JR; Espiner EA Aust N Z J Med; 1982 Feb; 12(1):43-7. PubMed ID: 7044357 [TBL] [Abstract][Full Text] [Related]
4. Residual B-cell function in type 1 (insulin-dependent) diabetes mellitus: its relation to clinical and metabolic features. Bonora E; Coscelli C; Butturini U Acta Diabetol Lat; 1984; 21(4):375-83. PubMed ID: 6397028 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Madsbad S; Faber OK; Binder C; McNair P; Christiansen C; Transbøl I Diabetes; 1978; 27 Suppl 1():262-4. PubMed ID: 344117 [TBL] [Abstract][Full Text] [Related]
6. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069 [TBL] [Abstract][Full Text] [Related]
7. C-Peptide reserve in insulin-dependent diabetes. Comparative responses to glucose, glucagon and tolbutamide. Mirel RD; Ginsberg-Fellner F; Horwitz DL; Rayfield EJ Diabetologia; 1980 Sep; 19(3):183-8. PubMed ID: 6997119 [TBL] [Abstract][Full Text] [Related]
8. Diurnal profiles of intermediary metabolites in insulin-dependent diabetes and their relationship to different degrees of residual B-cell function. Madsbad S; Faber OK; Binder C; Alberti KG; Lloyd B Acta Diabetol Lat; 1981; 18(2):115-21. PubMed ID: 7018146 [TBL] [Abstract][Full Text] [Related]
9. The relationship between residual insulin secretion and metabolic stability in type 1 (insulin dependent) diabetes. Lutterman JA; Benraad TJ; van 't Laar A Diabetologia; 1981 Aug; 21(2):99-102. PubMed ID: 7021291 [TBL] [Abstract][Full Text] [Related]
10. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Faber OK; Binder C Diabetes; 1977 Jul; 26(7):605-10. PubMed ID: 326604 [TBL] [Abstract][Full Text] [Related]
11. Residual B-cell function in insulin dependent (Type 1) and non insulin-dependent (Type 2) diabetics (relationship between 24-hour C-peptide excretion and the clinical features of diabetes). Gerö L; Korányi L; Tamás G Diabete Metab; 1983 Sep; 9(3):183-7. PubMed ID: 6360742 [TBL] [Abstract][Full Text] [Related]
12. [beta-Cell residual function in juvenile diabetes mellitus (author's transl)]. Schober E; Schernthaner G; Frisch H Monatsschr Kinderheilkd; 1980 Dec; 128(12):776-9. PubMed ID: 6109242 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-etide response to intravenous glucagon. Hendriksen C; Faber OK; Drejer J; Binder C Diabetologia; 1977 Dec; 13(6):615-9. PubMed ID: 338408 [TBL] [Abstract][Full Text] [Related]
14. Metabolic control and B cell function in patients with insulin-dependent diabetes mellitus secondary to chronic pancreatitis. Larsen S; Hilsted J; Tronier B; Worning H Metabolism; 1987 Oct; 36(10):964-7. PubMed ID: 3309547 [TBL] [Abstract][Full Text] [Related]
15. beta-cell function in children with diabetes. Ludvigsson J; Heding LG Diabetes; 1978; 27 Suppl 1():230-4. PubMed ID: 344114 [TBL] [Abstract][Full Text] [Related]
16. Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis. McNair P; Madsbad S; Christensen MS; Christiansen C; Faber OK; Binder C; Transbøl I Acta Endocrinol (Copenh); 1979 Mar; 90(3):463-72. PubMed ID: 425786 [TBL] [Abstract][Full Text] [Related]
18. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. Keymeulen B; Vandemeulebroucke E; Ziegler AG; Mathieu C; Kaufman L; Hale G; Gorus F; Goldman M; Walter M; Candon S; Schandene L; Crenier L; De Block C; Seigneurin JM; De Pauw P; Pierard D; Weets I; Rebello P; Bird P; Berrie E; Frewin M; Waldmann H; Bach JF; Pipeleers D; Chatenoud L N Engl J Med; 2005 Jun; 352(25):2598-608. PubMed ID: 15972866 [TBL] [Abstract][Full Text] [Related]
19. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Madsbad S; Krarup T; McNair P; Christiansen C; Faber OK; Transbøl I; Binder C Acta Med Scand; 1981; 210(3):153-6. PubMed ID: 7027749 [TBL] [Abstract][Full Text] [Related]
20. Residual beta-cell function in type II diabetes and evaluation of the hepatic insulin extraction. Toledo e Souza IT; Wajchenberg BL; Prestes Cesar F; Almeida Neto JS Horm Metab Res; 1983 Dec; 15(12):575-80. PubMed ID: 6363239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]